Ophthalmoscope SEC vs OptoView Usage & Stats
Spread the ophthalmologists' view to the world
Blindness continues to remain a major problem worldwide.WHO announced that at least a billion people have a visual impairment that can be prevented or has yet to be addressed. Over half of these blindness incidents were caused by cataracts.
We found that one of the major problems is that there is no diagnostic device in the areas where blindness is increasing.Therefore, we invented a solution that has the potential to overcome this problem. The solution, Smart Eye Camera (SEC), is a smart phone attachment that can record and evaluate ophthalmological images and video to help make a diagnosis online.
The Ophthalmoscope SEC is an attachment to the iPhone that allows the user to view the fundus and diagnose ophthalmologic diseases in the same way as an existing direct-view mirror.
Term and Condition(Japanese Only)
https://www.ouiinc.jp/terms_of_service/
- Apple App Store
- Free
- Medical
Store Rank
- -
Retinal Exams in the Palm of Your Hand
--The OptoView App--
Insight Optics has developed OptoView – a mobile telemedicine platform connecting primary care providers (PCPs) to local eye care specialists for assisted retinal screening.
OptoView enables primary care providers to record, store, and forward retinal exams to locally available eye care specialists who, along with our dedicated screening portal, review exam videos and generate detailed findings and follow-up reports.
OptoView is device-agnostic, meaning it can be used with any smartphone-enabled ophthalmoscope to:
• Record raw HD video of retinal examinations
• Store unlimited patient information and exam data
• Send exam videos to local eye care specialists in the OptoView network
• Access and generate PDF reports for reimbursement
The OptoView platform is a secure, HIPAA-compliant solution that brings rich telemedicine functionality to any smartphone ophthalmoscope.
Don’t let hindsight be 20/20!
- Apple App Store
- Free
- Medical
Store Rank
- -
Ophthalmoscope SEC VS. 
OptoViewDecember 17, 2024